Scarica l'app Stockscreener
1.23
6.96%
0.08
Dopo l'orario di chiusura:
1.23
Precedente Chiudi:
$1.15
Aprire:
$1.15
Volume 24 ore:
751.91K
Relative Volume:
0.51
Capitalizzazione di mercato:
$71.22M
Reddito:
$54.77M
Utile/perdita netta:
$15.24M
Rapporto P/E:
5.0493
EPS:
0.2436
Flusso di cassa netto:
$7.24M
1 W Prestazione:
+2.93%
1M Prestazione:
-44.09%
6M Prestazione:
-46.29%
1 anno Prestazione:
-45.58%
Intervallo 1D:
$1.15
$1.25
Intervallo di 1 settimana:
$1.125
$1.25
Portata 52W:
$1.08
$3.08
Spero Therapeutics Inc Stock (SPRO) Company Profile
Nome
Spero Therapeutics Inc
Settore
Industria
Telefono
857-242-1600
Indirizzo
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
1.23 | 68.32M | 54.77M | 15.24M | 7.24M | 0.2436 |
VRTX
Vertex Pharmaceuticals Inc
|
478.70 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
760.66 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
844.50 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.46 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
323.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Iniziato | Evercore ISI | Outperform |
| 2019-11-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-09-09 | Iniziato | Janney | Buy |
| 2018-02-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Iniziato | BofA/Merrill | Neutral |
| 2017-11-27 | Iniziato | Oppenheimer | Outperform |
| 2017-11-27 | Iniziato | Stifel | Buy |
Mostra tutto
Spero Therapeutics Inc Borsa (SPRO) Ultime notizie
SPRO|Spero Therapeutics Inc|Price:1.170|Chg%:-0.020 - TradingKey
Spero Therapeutics Appoints Dr. Debra Jeske Zack Chief Medical Officer to Lead SP001 Development - citybiz
Spero Therapeutics names Debra Zack as chief medical officer - Investing.com
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Spero Therapeutics names Debra Zack as chief medical officer By Investing.com - Investing.com Canada
Spero's Phase 2-Ready Antibody Has a New Clinical Lead - Stock Titan
Spero Therapeutics Inc (SPRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spero Therapeutics Inc (SPRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Spero Therapeutics Inc (SPRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
SPRO|Spero Therapeutics Inc|Price:1.195|Chg%:+0.005 - TradingKey
Spero Therapeutics Inc (SPRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spero Therapeutics Secures $105 Million Royalty Financing and Exclusive License for SP001 - Global Legal Chronicle
SPRO stock holds its ground on Spero Therapeutics financing and pipeline - Ad-hoc-news.de
Enterprise value to EBITDA forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Enterprise value to revenue forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to earnings forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to book forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to sales forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Innovent licenses IBI355 rights to Spero for up to $1.1bn - Yahoo Finance
Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Lice - GuruFocus
Spero Therapeutics secures $105 million royalty financing - The Pharma Letter
Spero licenses anti-CD40L antibody from Innovent for $1.1bn By Investing.com - Investing.com South Africa
Spero Therapeutics (SPRO) Secures Exclusive License for IBI355 - GuruFocus
Spero Therapeutics: 'Buy' Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO) - Seeking Alpha
Spero licenses anti-CD40L antibody from Innovent for $1.1bn - Investing.com UK
Spero signs $1.1 billion SP001 licensing deal - grafa.com
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion - Reuters
Spero Therapeutics secures $105m financing for drug development By Investing.com - Investing.com India
Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Licensing Agreement - GuruFocus
Spero Therapeutics Secures $105 Million Royalty Financing to Advance Immunology Pipeline - citybiz
Spero in-licenses Innovent’s antibody therapy (SPRO:NASDAQ) - Seeking Alpha
Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing - Moomoo
Spero Therapeutics (SPRO) Secures $105M Financing to Advance Imm - GuruFocus
Spero Therapeutics secures $105m financing for drug development - Investing.com
Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) - Yahoo Finance
Spero Therapeutics Licenses CD40L Antibody With Up to $1.05B Milestones, Secures $105M Royalty Financing - TradingView
Spero Therapeutics (Nasdaq: SPRO) inks SP001 deal and $105M royalty financing - Stock Titan
Spero Therapeutics shares fall after $105M KKR deal By Investing.com - Investing.com South Africa
Spero Therapeutics shares fall after $105M KKR deal - Investing.com UK
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties - The Manila Times
Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029 - Quiver Quantitative
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody - The Manila Times
Spero's $105M deal will support Phase 2 immunology drug SP001 - Stock Titan
Cambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunology - The Business Journals
Enterprise value to EBIT forward of Spero Therapeutics, Inc. – MUN:2HA - TradingView
MSN Money - MSN
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors - Yahoo! Finance Canada
Spero Therapeutics outlines its antibiotic pipeline as investors track regulatory progress - ad-hoc-news.de
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Spero Therapeutics Inc Azioni (SPRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spero Therapeutics Inc Azioni (SPRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rajavelu Esther | See Remarks |
Feb 06 '26 |
Sale |
2.36 |
87,917 |
207,484 |
1,012,091 |
| Keutzer Timothy | Chief Operating Officer |
Feb 06 '26 |
Sale |
2.36 |
18,652 |
44,019 |
742,506 |
| Keutzer Timothy | Chief Operating Officer |
Feb 03 '26 |
Sale |
2.14 |
24,224 |
51,839 |
764,629 |
| Keutzer Timothy | Chief Operating Officer |
Feb 02 '26 |
Sale |
2.20 |
18,891 |
41,560 |
788,853 |
| Keutzer Timothy | Chief Operating Officer |
Feb 04 '26 |
Sale |
2.24 |
3,471 |
7,775 |
761,158 |
| Rajavelu Esther | See Remarks |
Feb 02 '26 |
Sale |
2.20 |
18,442 |
40,572 |
1,100,008 |
| Rajavelu Esther | See Remarks |
Nov 07 '25 |
Sale |
2.37 |
40,270 |
95,440 |
869,450 |
| Mahadevia Ankit | Director |
Aug 28 '25 |
Sale |
1.97 |
6,572 |
12,947 |
703,294 |
| Keutzer Timothy | Chief Operating Officer |
Aug 28 '25 |
Sale |
1.97 |
1,695 |
3,339 |
739,744 |
0.98%
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):